Posted by Michael Wonder on 20 Oct 2021
FDA expands approval of Dupixent (dupilumab) to include children aged 6 to 11 years with moderate to severe asthma
20 October 2021 - Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomised Phase 3 trial, supporting potential as a best in class option.
The U.S. FDA has approved Dupixent (dupilumab) as an add-on maintenance treatment of patients aged 6 to 11 years with moderate to severe asthma characterised by an eosinophilic phenotype or with oral corticosteroid dependent asthma.
